STOCK TITAN

Adma Biologics - ADMA STOCK NEWS

Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.

Company Overview

ADMA Biologics Inc is a late-stage, end-to-end commercial biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty plasma-derived biologics. Focused on therapies for patients with primary immune deficiencies and those susceptible to certain infectious diseases, ADMA harnesses advanced bio-manufacturing techniques and stringent quality controls to produce immunoglobulin products that address critical therapeutic needs. Incorporating industry-specific terms such as "plasma-derived biologics," "biopharmaceutical manufacturing," and "FDA-approved processes," the company positions itself at the intersection of scientific innovation and operational excellence.

Core Business Model and Operations

The company’s business model is built on an integrated approach that encompasses several key operations:

  • Biomanufacturing: ADMA’s state-of-the-art manufacturing segment is dedicated to processing and refining plasma to produce high-quality immunoglobulin (IG) products. By deploying advanced production and yield enhancement techniques, the company maximizes output and maintains rigorous compliance with regulatory standards.
  • Plasma Collection Centers: ADMA operates specialized plasma collection centers which serve as the foundation for its production process. These centers ensure a consistent and high-titer plasma supply stream, critical to supporting the production of its specialty biologics.
  • Contract Services: The company also extends laboratory contracting services, including contract filling, labeling, and packaging, thereby diversifying its service offerings and reinforcing its role within the commercial biopharmaceutical ecosystem.

Product Portfolio and Regulatory Milestones

ADMA Biologics focuses on producing plasma-derived immunoglobulins for niche patient populations. The company’s product candidates — designed specifically for patients with immune deficiencies and those at risk for infectious diseases — undergo extensive clinical evaluations and regulatory scrutiny to ensure safety and efficacy. With notable FDA-approved manufacturing processes and a portfolio strengthened by patent protection, ADMA has built a reputation for compliance, scientific rigor, and quality. The company has strategically enhanced its product characteristics, such as optimized storage conditions, to better meet the practical needs of healthcare providers and patients alike.

Market Position and Competitive Landscape

Operating in a highly specialized sector of the biopharmaceutical industry, ADMA Biologics faces competition from both established global entities and emerging innovators. What differentiates the company is its integrated, end-to-end approach—from plasma collection to biologics production—which not only provides better control over quality but also ensures a resilient supply chain. ADMA’s emphasis on innovative manufacturing technologies, reinforced by strong regulatory approvals and intellectual property protections, contributes to its authoritative stance in the market. By focusing on a niche area of immunoglobulin therapies, the company maintains a competitive edge while addressing a critical unmet need among immunodeficient patients.

Expertise, Experience, and Trustworthiness

ADMA Biologics has cultivated a robust foundation of scientific expertise and operational experience. Its commitment to quality is demonstrated by adherence to stringent regulatory benchmarks and the continuous innovation of its manufacturing processes. Investors and stakeholders benefit from a transparent outlook on the company’s core strengths—integrated operations, strategic regulatory milestones, and a focus on high-titer plasma sourcing. Furthermore, the company’s diverse business segments work synergistically to create a comprehensive, resilient structure that appeals to analysts looking for depth in both operational excellence and market understanding.

Business Impact and Strategic Focus

At its core, ADMA Biologics is driven by a mission to enhance patient outcomes through specialized biologic therapies. By addressing critical needs in the treatment and prevention of immune deficiency diseases, the company not only reinforces its market significance but also contributes to improved clinical practices. Its commitment to quality, coupled with advanced biomanufacturing and innovative process enhancements, positions ADMA as a key player within the biopharmaceutical sphere. Each operational advancement is supported by a deep understanding of industry dynamics and a commitment to rigorous scientific validation, ensuring that every product meets the highest standard of care.

Conclusion

The detailed structure of ADMA Biologics reflects a well-integrated business model that combines state-of-the-art manufacturing, strategic plasma collection, and comprehensive regulatory compliance to deliver specialty plasma-derived biologics. Designed to serve a niche but critical segment of patients, the company’s efforts underscore a commitment to quality, scientific validation, and operational excellence. Whether examining its innovative production processes or its robust intellectual property portfolio, ADMA Biologics stands as a testament to deep industry expertise and stringent regulatory adherence, making it a subject of interest for investors and industry analysts alike.

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) announced that its President and CEO, Adam Grossman, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, at 7:55 a.m. ET. The event will be accessible via a webcast on the company's website, archived for 90 days post-event.

ADMA is focused on developing specialty plasma-derived biologics for immune-compromised patients and markets three FDA-approved products: BIVIGAM®, ASCENIV™, and NABI-HB®. The company operates a plasma fractionation facility in Boca Raton, Florida.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
-
Rhea-AI Summary

ADMA Biologics reported total revenues of $28.3 million for the first nine months of 2020, a 63% increase year-over-year. The third quarter generated $10.3 million, marking a 42% growth compared to Q3 2019. Despite revenue growth, net loss for the quarter was $16.9 million, attributed to rising costs and increased operational expenses. The company is ahead of schedule in expanding its plasma collection centers, aiming for five to ten new centers by 2025. ADMA's cash reserves rose to $59.7 million as of September 30, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.48%
Tags
-
Rhea-AI Summary

ADMA Biologics announced a live conference call on November 5, 2020, at 4:30 p.m. ET, to discuss its Q3 2020 financial results and business highlights. The call will be accessible via phone and an audio webcast, with an archived version available two hours post-event. ADMA specializes in manufacturing and marketing plasma-derived biologics, including ASCENIV™, BIVIGAM®, and NABI-HB®, approved by the FDA for treating immunodeficient patients. More information can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
conferences earnings
Rhea-AI Summary

ADMA Biologics, Inc. (Nasdaq: ADMA) is hosting an exclusive educational event at IDWeek 2020 on respiratory viral infections, featuring experts Dr. Michael Ison and Dr. Lisa Forbes Satter. The session on October 22 will focus on managing infections in immunocompromised patients. Additionally, new data on Streptococcus pneumoniae will be presented in an on-demand session. ADMA Biologics develops specialty plasma-derived biologics for immunodeficient patients, with FDA-approved products including ASCENIV™, BIVIGAM®, and NABI-HB® to combat infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
Rhea-AI Summary

ADMA Biologics, a biopharmaceutical company, will have its CEO Adam Grossman participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on September 14, 2020, at 4:30 p.m. ET. This event will provide insights into the company's operations and product offerings, focusing on specialty plasma-derived biologics for immunodeficient patients. A webcast of the event will be available on the ADMA website and archived for 90 days. ADMA manufactures three FDA-approved products for treating immune deficiencies and infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences
-
Rhea-AI Summary

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in several investor conferences in September 2020. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 2:30 p.m. ET, Cantor Virtual Global Healthcare Conference on September 17 at 11:20 a.m. ET, and Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 22 at 9:10 a.m. ET. Webcasts will be available on ADMA's website and archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
Rhea-AI Summary

ADMA Biologics reported $18 million in total revenues for the first half of 2020, reflecting a 78% increase year-over-year. Despite a 19% revenue growth in Q2 compared to 2019, the company faced disruptions due to COVID-19, affecting product testing and supply chains. ADMA opened a new plasma center and joined the CoVIg-19 Plasma Alliance. It anticipates generating $250 million in annual revenue within three to five years. However, net loss for Q2 reached $20.2 million, up from $13.2 million in Q2 2019, driven by increased operational costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.8%
Tags
-
Rhea-AI Summary

ADMA Biologics, Inc. (ADMA) announced a live conference call scheduled for August 5, 2020, at 4:30 p.m. ET to discuss its business highlights and financial results for Q2 2020, ending June 30, 2020. The call can be accessed via phone or through an audio webcast available on ADMA's investor relations website. The company is focused on manufacturing and developing plasma-derived biologics targeting immunodeficient patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences earnings
-
Rhea-AI Summary

ADMA Biologics announced the opening of its second plasma collection facility, ADMA BioCenters, in Knoxville, TN. This facility is part of ADMA's plan to establish 5 to 10 new centers by the end of 2022. A Biologics License Application (BLA) has been submitted to the FDA for approval, expected by mid-2021. The Knoxville center features modern equipment and amenities to enhance donor experience. Until FDA approval, ADMA can collect plasma, which will then be used for production of its FDA-approved immunoglobulin products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
Rhea-AI Summary

ADMA Biologics announced the approval of Martha J. Demski's election to its Board of Directors during the Annual Shareholder Meeting on June 18, 2020. Ms. Demski brings over 35 years of biotechnology experience, previously serving as CFO at Ajinomoto Althea and holding positions at Vical and the Sidney Kimmel Cancer Center. Her financial expertise is expected to bolster ADMA's growth, especially with products like BIVIGAM and ASCENIV. ADMA is focused on expanding its plasma collection facilities and developing novel immunoglobulin products for immunodeficient patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
management

FAQ

What is the current stock price of Adma Biologics (ADMA)?

The current stock price of Adma Biologics (ADMA) is $18.01 as of April 4, 2025.

What is the market cap of Adma Biologics (ADMA)?

The market cap of Adma Biologics (ADMA) is approximately 4.4B.

What is the primary focus of ADMA Biologics?

ADMA Biologics specializes in developing, manufacturing, and commercializing plasma-derived biologics for treating patients with immune deficiencies and certain infectious diseases. Its comprehensive operations ensure quality and regulatory compliance throughout the production process.

How does ADMA generate revenue?

Revenue is primarily derived from its integrated approach which includes advanced biomanufacturing of immunoglobulin products, plasma collection operations, and offering contract services such as filling, labeling, and packaging. This diversified model supports a stable and consistent income stream.

What distinguishes ADMA in the biopharmaceutical industry?

ADMA’s edge lies in its end-to-end operational strategy, combining specialized plasma collection with innovative manufacturing processes and a robust regulatory framework. This integration allows for superior quality control and efficiency compared to its competitors.

What role do plasma collection centers play in the company’s operations?

The plasma collection centers are a fundamental part of ADMA’s supply chain. They ensure a reliable, high-titer plasma supply necessary for producing its specialty biologics, thereby maintaining the overall quality and consistency of its final products.

How does the company ensure regulatory compliance and product quality?

ADMA adheres to stringent FDA-approved manufacturing processes and maintains a robust intellectual property portfolio. Rigorous clinical testing and validation protocols are employed to ensure that every product meets the high quality and safety standards required in the biopharmaceutical sector.

Are there any unique storage or handling features for ADMA's products?

Yes, the company has engineered product characteristics such as extended room temperature storage conditions. These enhancements not only improve product accessibility for healthcare providers but also optimize inventory management within the clinical setting.

How is ADMA positioned compared to other companies in its market?

ADMA differentiates itself through its integrated manufacturing and plasma collection processes, comprehensive regulatory approvals, and specialized focus on therapies for immune deficient patients. This combination of expertise and operational efficiency positions the company as a robust entity within its niche market.
Adma Biologics

Nasdaq:ADMA

ADMA Rankings

ADMA Stock Data

4.43B
228.42M
2.64%
88.42%
6.01%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RAMSEY